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Previewsincrease reactive oxygen species and
directly regulate blood pressure, thereby
linking innate immunity, endothelial
dysfunction, and hypertension. There are
a number of questions to be addressed
in future studies, including those concern-
ing basic science (such as why SDMA is
elevated in CKD, why elevated ADMA,
also seen in CKD, does not cause the
same dysfunction, and how TLR2 sig-
naling proceeds in the absence of TLR1
and/or TLR6), as well as those related to
the clinical implications. For example, it
is well established that atherosclerosis
begins early in life and, to date, all of the
risk factors in adults modulate the pro-
gression of the disease in the teenage
years (McGill et al., 2000). It is also known
that the earlier in life risk factor reduction
is achieved, the greater the decrease in
life-long risk of CVD disease (e.g., Cohen
et al., 2006). With this in mind, finding630 Immunity 38, April 18, 2013 ª2013 ElsevSDMA-modified HDL in children with
CKD raises the question that if further clin-
ical studies support SDMA and the asso-
ciated pathway as important therapeutic
targets, how early in life should one begin
to avoid paying the toll?REFERENCES
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It has been unclear whether an innate lymphoid cell (ILC) counterpart to the T helper 1 cell type exists. New
studies, including Fuchs et al. (2013) in this issue of Immunity, identify T-bet+IFN-g+ ILC1 that accumulate in
the inflamed intestine of IBD patients.A burgeoning body of recent literature has
described a variety of innate lymphoid cell
(ILC) populations arising from a common
lymphoid progenitor, that lack rearranged
antigen receptors and do not express
myeloid or dendritic cell markers (Spits
and Cupedo, 2012). ILCs are found at
mucosal sites, such as the gastrointes-
tinal tract and lung, where they respond
to tissue stress or infection by secreting
cytokines that promote innate immunity
and tissue repair, but which may also
contribute to immunopathology (Spits
and Cupedo, 2012). ILC subpopulations
are heterogeneous and have been classi-
fied according to their expression of key
transcription factors and effector cyto-kines, which mirror the polarization of
different CD4+ T helper subsets (Spits
et al., 2013; Spits and Cupedo, 2012).
Thus, ILC populations that express
GATA-3 and secrete T helper 2 (Th2) cell
related cytokines are termed ILC2,
whereas ILCs that express RORgt and
secrete Th17 or Th22 cell related cyto-
kines are termed ILC3 (Spits et al.,
2013). Until now, conventional natural
killer (NK) cells were regarded as the
innate cell Th1 doppelganger. However,
three recent studies (Bernink et al., 2013;
Fuchs et al., 2013; Klose et al., 2013),
including one in this issue of Immunity
(Fuchs et al., 2013), have identified
mucosal Th1 cell innate counterparts inhumans and mice. Termed ILC1, these
populations express the transcription fac-
tor T-bet and release IFN-g in response to
cytokines such as interleukin-12 (IL-12),
IL-15, and IL-18.
The search for novel human ILC popu-
lations was initially conducted on tonsil
samples.Within the CD56+CD3 cell frac-
tion, Fuchs et al. (2013) identified two
distinct populations (NKp44+CD103+ ILC
and NKp44CD103 ILC) that had the
capacity to secrete high amounts of
IFN-g, CCL4, and TNF-a in response to
the cytokines IL-12 and IL-15. Consistent
with their Th1-like profile, the ILC1
subsets expressed higher amounts of
T-bet and lower amounts of RORgt and
Figure 1. ILC1 Populations Contribute to Protection and Pathology in the Intestine
Subsets of T-bet+IFN-g+ ILC1 in the murine intestine include intraepithelial ILC1 that respond to IL-12 and
IL-15, lamina propria ILC1 that respond to IL-12 and IL-18, and NK cells. RORgt+ ILC3 may switch toward
T-bet+ ILC1 cells in response to environmental factors, such as IL-12. ILC1-derived Th1 cytokines may
activate protective innate immunity but may also contribute to intestinal pathology.
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PreviewsAHR than ILC3. Independently, Bernink
et al. (2013) identified a population of
c-KitNKp44 ILC that had similarities to
Th1 cells, including high expression of
IFN-g, T-bet, CXCR3, and CCL3. These
ILC1 secreted IFN-g in response to IL-12
and IL-18 and were phenotypically and
developmentally distinct from conven-
tional NK cells.
Both studies subsequently demon-
strated that human ILC1 were also pre-
sent in the intestine. The association
between Th1-cell cytokine responses
and intestinal pathology in Crohn’s dis-
ease (CD) prompted evaluation of ILC1
cells in CD lesions. Bernink et al. (2013)
observed that the intestinal lamina propria
(LP) of CD patients contained substan-
tially higher frequencies of c-KitNKp44
ILC1 compared to noninflamed controls.
Furthermore, adoptive transfer of human
fetal hematopoietic stem cells (HSC) into
transgenic mice lacking lymphocytes,
NK cells, and ILCs, demonstrated that
human ILC could reconstitute the intesti-
nal ILC compartment inmice. Subsequent
induction of intestinal inflammation by
treatment with dextran sodium sulfate
was again accompanied by a dramatic in-
crease in accumulation of c-KitNKp44
ILC1 in the inflamed colon.
In contrast to the lamina propria
ILC populations, Fuchs et al. (2013)
demonstrated that the NKp44+CD103+
ILC1 subset resided within the epithelial
layer of tonsil and intestine, suggesting
that, like intraepithelial (IEL) T cells, theymay respond to stress or infection of
the intestinal epithelium. Indeed, the
NKp44+CD103+ ILC1 subset expressed
additional IEL surface markers and
secreted IFN-g following coculture with
a TLR2-stimulated intestinal epithelial
cell (IEC) line, although the signals
involved were not identified. Although
NKp44+CD103+ ILC1 constituted only a
small fraction of IEL found in healthy intes-
tine, there was a dramatic increase in
their abundance in inflamed ileal samples
taken from CD patients. Murine counter-
parts of human intraepithelial ILC1 were
identified as CD160+NKp46+NK1.1+ ILC
that also produced IFN-g in response to
stimulation with IL-12 and IL-15 (Fuchs
et al., 2013). In a model of innate
immune-mediated colitis, induced by
administration of agonistic CD40 mAbs
to Rag1/ mice, intraepithelial ILC1 in
the small bowel rapidly secreted IFN-g,
and antibody-mediated depletion of
NK1.1+ cells led to reduced colitis.
Together with previous studies, this sug-
gests that ILC are the key source of path-
ogenic IFN-g in this model (Buonocore
et al., 2010; Uhlig et al., 2006; Vonarbourg
et al., 2010).
Together, these findings indicate that
at least two subsets of human ILC1
accumulate in the inflamed intestine
in Crohn’s disease patients; a CD56+
NKp44+CD103+ ILC1 subset that resides
in the epithelium and responds to IL-12
and IL-15 and a CD56c-KitNKp44
ILC1 subset in the lamina propria thatImmunityresponds to IL-12 and IL-18 (Figure 1).
Although the functional contribution of
ILC1 to pathology remains to be deter-
mined, IFN-g production is postulated
to be a key inflammatory mediator.
However, to date, clinical trials of IFN-g
blockade in Crohn’s disease have re-
ported only limited beneficial effects;
therefore, the therapeutic utility of target-
ing IFN-g remains to be demonstrated
(Reinisch et al., 2010). It will be important
to examine whether ILC1 populations are
associated with other intestinal immune
disorders. For example, the IL-15 respon-
sive intraepithelial ILC1 subset could
potentially be involved in celiac disease,
where IEL lymphocytosis is a hallmark of
this Th1-cell and IL-15 driven immunopa-
thology (Abadie et al., 2011).
The parallels between ILC and CD4+
Th cell subsets have stimulated investiga-
tion of their differentiation pathways and
plasticity. Indeed, Bernink et al. (2013)
demonstrated that c-Kit+NKp44RORgt+
ILCs could give rise to either ILC1 or
to ILC3 depending on the cytokine envi-
ronment. Furthermore, c-KitNKp44
ILC1 cells could be derived from
NKp44+RORgt+ ILC3 cells following cul-
ture with IL-12 and IL-2. Thus, ILC1 can
differentiate from other ILC populations,
including ILC3, in response to environ-
mental cytokines like IL-12 (Figure 1).
Further clues to the potential differenti-
ation pathways and functions of ILC1
were provided by Klose et al. (2013),
who reported that the mouse small intes-
tinal LP harbored a population of
CCR6RORgt+T-bet+ ILC that readily
produced IFN-g and TNF-a, but ex-
pressed little IL-22, similar to ILC1. These
CCR6RORgt+T-bet+ ILC differentiated
from CCR6RORgt+ ILC in response to
environmental stimuli, such as com-
mensal microbiota, through increased
expression of T-bet, which in turn pro-
moted expression of IFN-g and NKp46.
During experimental Salmonella typhimu-
rium infection, NKp46+RORgt+T-bet+ ILC
mediated early innate IFN-g secretion
that helped maintain the secretion of bar-
rier-protective mucus. Conversely, the
enterocolitis induced by S. typhiumurium
infection was attenuated in mice lacking
NKp46+RORgt+IFN-g+ ILCs, again sug-
gesting that activation of ILC1 cells
could contribute to intestinal pathology.
Future studies should further define the
role of ILC1 in early protective immunity38, April 18, 2013 ª2013 Elsevier Inc. 631
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IFN-g plays a key protective role. More-
over, the early IFN-g responses to which
ILC1 contribute might sensitize antigen-
presenting cells and shape the local
microenvironment to influence subse-
quent effector T cell responses.
These findings extend the diversity of
human ILC subsets by describing unique
subsets of ILC1 cells that secrete IFN-g,
which may impact protection and pathol-
ogy in the gut. In addition, the flexible
expression of key transcription factors
exhibited by ILCs suggests that func-
tional plasticity is an intrinsic property
utilized by both innate and adaptive lym-
phocytes to respond to distinct types of
pathogens.632 Immunity 38, April 18, 2013 ª2013 ElsevREFERENCES
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